Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Leidermark

Showing results (1-10 of 1) with videos related to

Pageof 1
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal RadioimmunotherapyErik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Pageof 1

Showing results (1-10 of 1) with videos related to

Sort By:
Pageof 1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal RadioimmunotherapyErik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Pageof 1